Novartis restructure marks break from expansion

Novartis restructure marks break from expansion Operating margins have declined for the past two years and another $ 3bn is expected to be knocked o...


Novartis restructure marks break from expansion
Operating margins have declined for the past two years and another $ 3bn is expected to be knocked off sales this year because of looming generic competition for its Diovan blood pressure treatment and Gleevec cancer drug. In response, Mr Jimenez has …
Read more on Financial Times

Leave a Reply